Alcidion (ASX:ALC) share price slumps despite 'strong growth'

The Alcidion Group (ASX: ALC) share price is on the slide today following the company's release of its Q3 results. Click on to find out more.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Alcidion Group Ltd (ASX: ALC) shares are on the slide today despite the company reporting "strong organic growth" in its March quarterly update.  At the time of writing, the Alcidion share price is trading 2.6% lower at 37.5 cents. In comparison, the All Ordinaries Index (ASX: XAO) is currently sitting 0.02% higher. 

Let's take a look at how the health-focused IT company has been performing. 

Quarter highlights

In a statement to the ASX this morning, Alcidion released its Q3 results for FY21. During the quarter, the company generated $2.8 million of positive cash flow. For the financial year so far, however, cash flow is currently negative $500,000.

Alcidion generated $11.5 million of customer receipts during the quarter. This constitutes just over half of the company's entire revenue for the financial year up to 31 March. $6.1 million of the $11.5 million was generated by NHS Trust customers in the United Kingdom.

The group expects contracted revenue for the financial year to total $24.7 million, $15.9 million of which will be recurring and $8.8 million will be non-recurring.

This month, Alcidion announced it had acquired ExtraMed – a UK patient flow software company – for $9.6 million and won a $21 million contract with the Australian Department of Defence as part of a consortium. The announcements sent the Alcidion share price to an all-time high.

Alcidion says the ExtraMed purchase will add $2.7 million in revenue during FY22 and $500,000 in earnings before interest, taxes, depreciation, and amortisation (EBITDA).

The group has $15.3 million in cash reserves currently. It expects to bolster its stash by an extra $6.6 million from a proposed capital raising endeavour.

Management commentary

Alcidion managing director Kate Quirke said of today's update:

Alcidion has delivered another quarter of strong organic sales growth in the UK, Australia and New Zealand, with contracted revenue of $24.7M expected to be recognised in FY21, excluding revenue from the acquisition of ExtraMed.

Having already surpassed our FY20 revenue figure by 33%, we now enter a new phase following the acquisition of ExtraMed, which strengthens our current patient flow offering and puts us into a market leading position in the UK, with 27 NHS Trusts as customers. We are already moving to integrate these businesses and engage with our expanded client base in this market.

Alcidion share price snapshot

Over the past 12 months, the Alcidion share price has increased by around 124%. In fact, just in the last month, the company's value has appreciated by more than 20%.

Given its current valuation, Alcidion has a market capitalisation of $395 million.

Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »